BPMUF (Basilea Pharmaceutica) Cyclically Adjusted PB Ratio: (As of Aug. 30, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BPMUF Basilea Pharmaceutica Ltd BPMUF
57 GF Score
Price $77.40
GF Value $68.74
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Basilea Pharmaceutica Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Basilea Pharmaceutica  (OTCPK:BPMUF) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Basilea Pharmaceutica Cyclically Adjusted PB Ratio Related Terms


Basilea Pharmaceutica Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Basilea Pharmaceutica's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Basilea Pharmaceutica Cyclically Adjusted PB Ratio Chart

Basilea Pharmaceutica Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Basilea Pharmaceutica Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

BPMUF vs VRTX, REGN, RVMD: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Basilea Pharmaceutica's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Basilea Pharmaceutica Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Basilea Pharmaceutica's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Basilea Pharmaceutica's Cyclically Adjusted PB Ratio falls into.


BPMUF
57GF Score
Basilea Pharmaceutica Ltd BPMUF
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Basilea Pharmaceutica Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Basilea Pharmaceutica's Cyclically Adjusted Book per Share for the fiscal year that ended in Dec25 is calculated as:

For example, Basilea Pharmaceutica's adjusted Book Value per Share data for the fiscal year that ended in Dec25 was:

Adj_Book=Book Value per Share/CPI of Dec25 (Change)*Current CPI (Dec25)
=13.061/107.2000*107.2000
=13.061

Current CPI (Dec25) = 107.2000.

Basilea Pharmaceutica Annual Data

Book Value per Share CPI Adj_Book
201612 -3.176 99.380 -3.426
201712 -3.862 100.213 -4.131
201812 -6.257 100.906 -6.647
201912 -8.781 101.063 -9.314
202012 -10.570 100.241 -11.304
202112 -5.374 101.776 -5.660
202212 -1.861 104.666 -1.906
202312 -0.964 106.461 -0.971
202412 7.514 107.128 7.519
202512 13.061 107.200 13.061

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Basilea Pharmaceutica (BPMUF) Overvalued in 2026?

Based on GuruFocus' analysis, Basilea Pharmaceutica stock appears to be overvalued. The current stock price of $77.40 is trading 12.6% above its estimated GF Value™ of $68.74. GuruFocus considers Basilea Pharmaceutica to be Modestly Overvalued.

Key valuation signals for BPMUF:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: $68.74 vs. price of $77.40 (12.6% above fair value)
  • GF Score™: 57/100 with 5 warning signs

No single metric tells the full story. See the BPMUF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Basilea Pharmaceutica Business Description

Address Hegenheimermattweg 167b, Allschwil, CHE, 4123
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.
57GF Score

Get the complete analysis for BPMUF

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$77.40
Price
$68.74
GF Value